NIASPAN: Updated Information from Cardiovascular Prevention Trial

Updated Information from Cardiovascular prevention trial, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH)

On May 26, 2011, Abbott distributed information regarding an interim analysis of the AIM-HIGH study which investigated NIASPAN® (niacin extended-release tablets) in combination with simvastatin versus simvastatin. The final study results were announced today at the American Heart Association Scientific Sessions 2011 and published in the New England Journal of Medicine. We would like to inform you of the final results of the AIM-HIGH Study.


Click to read more.

This entry was posted in Industry Updates, Manufacturers Updates and tagged , . Bookmark the permalink.

Comments are closed.